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ABSTRACT: Background: Spinal muscular atrophy (SMA) is a devastating rare disease that affects individuals regardless of ethnicity,
gender, and age. The first-approved disease-modifying therapy for SMA, nusinursen, was approved by Health Canada, as well as by
American and European regulatory agencies following positive clinical trial outcomes. The trials were conducted in a narrow pediatric
population defined by age, severity, and genotype. Broad approval of therapy necessitates close follow-up of potential rare adverse events
and effectiveness in the larger real-world population. Methods: The Canadian Neuromuscular Disease Registry (CNDR) undertook an
iterative multi-stakeholder process to expand the existing SMA dataset to capture items relevant to patient outcomes in a post-marketing
environment. The CNDR SMA expanded registry is a longitudinal, prospective, observational study of patients with SMA in Canada
designed to evaluate the safety and effectiveness of novel therapies and provide practical information unattainable in trials. Results: The
consensus expanded dataset includes items that address therapy effectiveness and safety and is collected in a multicenter, prospective,
observational study, including SMA patients regardless of therapeutic status. The expanded dataset is aligned with global datasets to
facilitate collaboration. Additionally, consensus dataset development aimed to standardize appropriate outcome measures across the
network and broader Canadian community. Prospective outcome studies, data use, and analyses are independent of the funding partner.
Conclusion: Prospective outcome data collected will provide results on safety and effectiveness in a post-therapy approval era. These data
are essential to inform improvements in care and access to therapy for all SMA patients.
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RÉSUMÉ : Un registre national des cas d’amyotrophie spinale en vue d’obtenir des données probantes basées sur l’expérience des patients.
Contexte : L’amyotrophie spinale (AS) est une maladie rare et dévastatrice qui affecte les individus indépendamment de leur origine ethnique, de leur sexe
et de leur âge. Le premier traitement modificateur de cette maladie, le nusinursen, a été approuvé par Santé Canada ainsi que par des agences
réglementaires américaines et européennes à la suite de résultats encourageants obtenus dans le cadre d’essais cliniques. Ces derniers ont été effectués sur
une population restreinte de jeunes patients recrutés en fonction de leur âge, de la gravité de leur AS et de leur génotype. On le sait, l’approbation à plus
grande échelle d’un traitement nécessite un suivi étroit de ses rares et potentiels effets indésirables et de son efficacité au sein d’une population réelle
beaucoup plus importante. Méthodes : À cet égard, le Canadian Neuromuscular Disease Registry (CNDR) a entrepris, avec diverses parties prenantes,
une démarche itérative visant à élargir l’ensemble des données actuelles au sujet de l’AS, et ce, afin de saisir les aspects se rapportant de façon pertinente à
l’évolution de l’état de santé des patients dans un contexte de vigilance post-marketing d’un traitement. De fait, ce registre élargi du CNDR au sujet de
l’AS repose sur une étude observationnelle longitudinale et prospective de patients canadiens atteints de l’AS. Cette étude a été conçue pour évaluer la
sécurité et l’efficacité des nouveaux traitements et fournir des renseignements pratiques impossibles à obtenir dans le cadre d’essais cliniques. Résultats :
De façon consensuelle, ces données élargies ont inclus des aspects tenant compte de l’efficacité du traitement et de sa sécurité. Elles ont été collectées lors
d’une étude menée dans plusieurs établissements de santé au sujet de patients atteints d’AS, et ce, quel que soit le niveau de soins qui leur étaient
prodigués. Ces données élargies étaient aussi conformes à l’ensemble des données obtenues précédemment afin de faciliter la collaboration. De plus, cette
approche consensuelle dans l’élaboration d’un ensemble de données a pour objectif de standardiser de manière appropriée les instruments de mesure de
l’évolution de l’état de santé des patients dans ce réseau et plus largement au Canada. Enfin, soulignons que tant les études prospectives portant sur
l’évolution de l’état de santé des patients, l’utilisation des données que les analyses effectuées sont demeurées indépendantes du bailleur de fonds.
Conclusion : Ces données prospectives quant à l’évolution de l’état de santé des patients atteints d’AS offriront, en lien avec le nusinursen, des résultats en
matière de sécurité et d’efficacité dans un contexte de suivi « post-approbation » des traitements. Ces données sont également essentielles pour en savoir
davantage à propos des améliorations aux soins et de l’accès aux traitements pour tous les patients.
Keywords: Real-world evidence, Spinal muscular atrophy, Registry, Rare disease
doi:10.1017/cjn.2020.111 Can J Neurol Sci. 2020; 47: 810–815
BACKGROUND
Spinal muscular atrophy (SMA) is a rare neuromuscular
disease that affects 1:10 000 people.1 It is caused by mutation
that results in the non-expression of the survival motor neuron
gene (SMN1) which leads to the degeneration of motor neurons
in the spinal cord, with muscle weakness and atrophy. SMA is
a heterogeneous disease that has historically been clinically
classified according to age of onset and highest motor milestone
achieved without disease-modifying therapy.2 The most severe
type has the highest incidence with onset in infancy. These
infants are unable to sit without support, and most patients do
not survive 2 years without ventilation support.3,4 Recent
advances have led to the development of new therapies: two in
clinical use and several others in clinical trials.5–7
With the emergence of these new treatments, there is a need to
monitor patients over time to provide real-world evidence on
effectiveness and adverse reactions. Patient registries provide an
important platform for researchers to benchmark national stan-
dards, monitor trends in patient characteristics, and, importantly,
monitor clinical outcomes in a real-world environment.
While randomized controlled trials remain the gold standard
for evaluating clinical efficacy and safety of therapies, the
generalizability of findings from the homogenous study partici-
pants who often lack significant comorbidities may be low. The
real-world effectiveness must be assessed when therapies are
incorporated into general practice across a broader range of
patients with multiple comorbidities, variable disease severity,
and over a longer time frame.
In order for registries to successfully undertake post-approval
therapy monitoring with high-quality observational data, a well-
defined consensus dataset and agreed set of clinical outcomes,
systematic follow-up of all patients, and clear analysis plan are
required.8,9
The purpose of this article is to describe the development of a
registry dataset for real-world evidence to inform the use, safety,
and effectiveness of SMA therapies in children and adults.
METHODS
Study Design
The Canadian Neuromuscular Disease Registry (CNDR)
is a nationwide pan-neuromuscular disease registry that collects
SMA-specific data from patients in 31 neuromuscular clinics
across Canada and currently (as of March 2020) follows 250
SMA patients. The CNDR consists of a network 15 pediatric and
16 adult neuromuscular clinics with broad geographic spread
across Canada (Supplemental Table 1).
In anticipation of the approval of nusinersen to treat SMA,
the CNDR SMA dataset was expanded to capture more relevant
outcomes that will help identify adverse drug reactions and assess
the effectiveness of SMA therapies in the broader real-world
population. The objective of this prospective multicenter obser-
vational study was to obtain a better understanding of the new
natural history of SMA by collecting data from all patients
regardless of therapeutic status. Secondary objectives included
establishing pragmatic methods to assess disease progression
and therapeutic effectiveness through both case–control study
(exposed vs. non-exposed), and analysis of patient outcomes
compared to their own baseline values. Through the study, we are
monitoring therapeutic effect profiles to inform SMA manage-
ment plans.
The CNDR is an active multicenter prospective registry
used as a research infrastructure tool (https://cndr.org/). In order
to define a consensus dataset, iterative survey methodology and
consensus discussions were utilized to select appropriate data
items for inclusion. The SMA expanded dataset was developed
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by the CNDR SMA Working Group which is comprised of
neurologists and basic scientist experts from across Canada.
Additional input was sought from other Canadian physicians
following SMA patients as well as external partners such as
patient organizations, global collaborators, and industry. Final
decisions on inclusion of dataset items were made by the
SMA Working Group. In parallel, global collaborators in the
TREAT-NMD Registry Committee were similarly developing
a new natural history dataset for use across the network of
over 50 SMA registries around the world. Included in the
collaborative global efforts to align data collection were other
national and regional initiatives including the US CureSMA
registry, the German SMArtCare initiative,10 and the interna-
tional SMA Consortium (Italian, UK, and USA) iSMAC
initiative. This international effort also informed the develop-
ment of the Canadian dataset.
All individuals diagnosed with genetically confirmed 5q-SMA
who are seen at CNDR-affiliated clinics and provide informed
consent are eligible to participate in the study. Each participating
clinic obtained research ethics board approval and written in-
formed consent and assent, as appropriate, from participants
and/or their legal guardians. Patients can self-register directly
with the National Office and release their clinical records for data
entry, which is helpful for less severely affected, primarily adult-
onset patients who are less likely to attend a specialty neuromus-
cular clinic.
Data Collection, IT Platform, and Data Quality
Patient data are collected through a web-based portal, utilizing
the REDCap (Research Electronic Data Capture) electronic
data capture tool.11 REDCap is a secure, web-based application
designed to support data capture for research studies that provides
an intuitive interface for validated data entry, audit trails, and
import and export capabilities.
The SMA dataset contains 12 standardized electronic data
capture forms: registration; visit info and anthropometric mea-
sures; status, clinical trials, and registries; diagnosis; genetics;
neuromuscular; respiratory; interventions; medical history;
electrophysiology and biomarkers; sociodemographics; and
patient-reported outcome measures.
Alongside items included in the existing minimal dataset
(clinical diagnosis, age, living status, genetic results (SMN1,
SMN2 copy number, family history), current and best lifetime
motor milestone achieved, wheelchair use, ventilation use, forced
vital capacity, and feeding tube use), additional items were
included to address safety and effectiveness of novel therapies.
The expanded dataset items included medications, treatments
(including start and stop date, administration route, reason
for discontinuation), surgeries and therapies, hospitalizations,
comorbidities, and motor outcome assessments. Additionally,
expansion of encouraged (i.e., non-mandatory) items encom-
passed biomarkers and electrophysiology, patient-reported out-
come measures, and sociodemographics. A copy of the complete
dataset is available in Appendix A.
While numerous motor outcome assessment measurements
and scales for SMA patients currently exist, the CNDR has
encouraged the use of the procedure developed by Pechmann
et al. in determining the most appropriate measure for a given
patient based on type of SMA and ambulatory status.10 The
preferred assessments for infantile onset included either the
Children’s Hospital of Philadelphia Infant Test of Neuromus-
cular Disorders (CHOP-INTEND) or the Hammersmith Infant
Neurological Examination (HINE) section 2. For later onset
individuals, preferred measures included the Hammersmith
Functional Motor Scale Expanded (HFMSE), the Revised
Upper Limb Module (RULM), and the 6-minute walk test
(6MWT) (depending on ambulatory status). Additionally, WHO
motor milestones can be assessed for all SMA patients
(Table 1).12–27 All motor outcome measures are conducted by
qualified physiotherapists, neurologists, or physiatrists who
have attended a training session specific to performing these
measures in the SMA population.
Regardless of therapeutic status (receiving nusinersen or not),
the schedule of events includes data collection and outcome
assessments during routine clinic visits every 6–12 months.
All data are entered by trained staff at the affiliated clinics
or national office from data collected during routine clinical
encounters. For patients who self-register and release their medi-
cal records, data are entered by trained staff at the National
CNDR Office. Entered clinical data are only accessible to site
Table 1: Motor outcome measures
Outcome measure Age Current milestone achieved Minimal clinical important difference References
CHOP-INTEND 0+ Non-sitters Unknown Glanzman (2010)12, Glanzman (2011)13,
Finkel (2016)14, Kolb (2016)15
6MWT 2+ years Ambulators Unknown Dunaway Young (2016)16, Mazzone E
(2013)17
HFMSE 2–45 years Sitters; ambulators An increase of >2 points in total score is
unlikely in untreated SMA type II and III
patients.Patient and caregivers consider
a 1-point increase meaningful.
O’Hagen (2007)18, Glanzman (2011)13,
Mercuri (2016)20, McGraw (2017)21,
Pera (2017)22
RULM 2+ years Sitters; ambulators Unknown Mazzone (2017)17, Pera (2019)23
HINE (section 2) 2–24 months All A score of >1 point for any given milestone is
highly unlikely in untreated SMA type I
patients.
Haataja (1999)24, De Sanctis (2016)25,
Bishop (2018)26
WHO motor milestones All All Unknown WHO Multicenter Growth Reference Study
Group 200627
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physician-investigators or their delegates, as well as national
office staff. Information is encrypted for storage and subject to
all national and provincial regulations for the protection of
personal health information.
Data quality is ensured through design of the data collection
platform (basic data validation to reduce the entry of implausible
values), concise data definitions, central training of data entry
personnel across clinical sites, and remote auditing at the
National Office. Auditing controls systematically applied
through the REDCap software include missing values, field
validation errors (out of range and incorrect data type), and
outliers for numerical fields. Patient identifiers are collected
centrally to allow provision for patient notifications of research
opportunities, and as such are utilized to confirm that there are
no duplicate registrations.
Analyses
Analyses will be performed using therapy naïve patients as a
control comparator group, as well as by comparing individual
patient outcomes over time with their own baseline values.
Descriptive statistics such as means, standard deviations, frequen-
cies, and percentages will be used to summarize participant demo-
graphics, clinical characteristics, and motor assessment outcomes at
baseline. Specifically, participants with complete data at all the
measurement points will be compared to those with incomplete data
over the 1-year period across baseline demographic and clinical
characteristics. Mixed-effects regression analyses will be used to
model the association between longitudinal changes in motor
outcome assessment scores. Participants’ baseline demographic
and clinical characteristics, and type of treatment received will be
modeled as fixed-effects factors, while variations across CNDR
clinics will be modeled as random effects. A spline function will
be used to determine the best functional relationship between
continuous factors and longitudinal change in each motor assess-
ment outcome. A repeated measures covariance will assume either
unstructured or first-order autoregressive structures. The Akaike
Information Criterion will be used to determine the model with the
best fit. Statistical significance will be evaluated at α= 0.05. All
analyses will be conducted in SAS 9.4.28
To assess the robustness of study conclusions to missing data,
descriptive analyses will be used to summarize the patterns of
missing data on both predictors and each longitudinal motor
outcome assessment over the 1-year period. Logistic regression
will be used to examine the differences between participants with
complete data and those with incomplete data. Missing data will
be handled using mean imputation, Hot-Deck imputation, and
Monte Carlo Markov Chain multiple imputation methods.29
Sensitivity analysis will be conducted with respect to missing
data by examining how conclusions change for different missing
data methods.
Data Use and Disclosure
The dataset developed will be used in prospective research
projects with access to de-identified data available to researchers
pending application to, and subsequent approval by the CNDR
advisory committee and SMA Working Group. To enable
international data sharing and international collaboration, the
dataset items have been aligned where possible with approved
outcomes by various national and regional SMA registries in the
TREAT-NMD SMA Registry group.10
Ethics
All clinical sites participating in the study must have ethics
approval. All patients participating in this study must provide
written informed consent to participate in the CNDR.
Financing
Biogen has provided financial support for this expanded
SMA registry and the collection of data regarding motor outcome
assessments. The CNDR is solely responsible for data protection
and retains independent rights to publish on any data collected.
RESULTS AND DISCUSSION
SMA is a devastating neuromuscular disease for which, until
recently, there was no effective treatment. Novel therapies
show promising results in clinical trials, which has translated
into regulatory approval for clinical use; however, further study is
required to assess long-term impacts. Prospective data collection
following approval is often captured through large Phase 4
clinical trials or epidemiologic studies at a significant cost. While
registries do not have all of the controls to evaluate the efficacy of
a drug, they provide valuable long-term and large-scale data in
the real world at a fraction of the cost of controlled studies.30,31
Use of disease-specific patient registries for post-marketing
surveillance of new therapies is increasing in Europe, the
USA, and Canada and is recognized as a useful tool to monitor
patients.32–34
The CNDR is an established network of neuromuscular clinics,
with best practice registry data collection procedures35–37, and is,
therefore, an ideal setting to implement real-world evidence gen-
eration. The network of participating neuromuscular physicians
ensures that appropriate measures are selected for use and are
collected with sufficient completeness and accuracy. Importantly,
data generated from this study will continue to address gaps in our
knowledge of clinical effectiveness of novel SMA therapies as they
come to market – especially in specialty populations that might be
excluded or under-represented in clinical trials. The SMA registry
expanded dataset was developed as a disease-specific registry that
collects data from individuals regardless of therapeutic status. The
use of disease-specific registries for post-marketing assessments of
safety and effectiveness has international consensus in both SMA
and other rare diseases from regulators, the academic community,
and patient organizations.38
In conclusion, the CNDR SMA registry has been expanded
to capture relevant longitudinal data to examine long-term
safety and effectiveness of available and emerging therapies in
a real-world setting. As a dynamic registry that can adapt to new
developments in SMA, the dataset will continue to evolve to
accommodate changes in the SMA landscape including innova-
tive outcome measures and novel therapies. Additionally, the
expanded dataset will provide the framework for future compar-
ative effectiveness studies when additional treatments are clini-
cally available.
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